Merck is one of several businesses focusing on lipoprotein(a), whose greater levels are linked to a higher risk of negative cardiovascular consequences.

Merck stated on Tuesday that it is investing $200 million to collaborate with Jiangsu Hengrui, a Chinese company, to develop its experimental small molecule for cardiovascular care, HRS-5346. Merck will also risk an extra $1.77 billion under the partnership agreement to meet specific commercial, regulatory, and development targets. In the meantime, if regulatory clearance is obtained, Hengrui will be eligible to receive royalties on the net sales of HRS-5346. With the exception of the Greater China area, Tuesday's agreement will encompass all global areas.

Assuming antitrust approvals and other standard requirements are met, Merck and Hengrui anticipate closing the purchase in the second quarter of 2025.

Lipoprotein(a) is inhibited by HRS-5346. High levels of this low-density lipoprotein, sometimes referred to as Lp(a), have been associated with an increased risk of negative cardiovascular events. Because of its widespread use, the molecule has become a desirable target for pharmaceutical firms in recent years. Merck said on Tuesday that around 1.4 billion people globally had elevated Lp(a) levels.

Although little is known about the precise mode of action of HRS-5346, Merck Research Laboratories president Dean Li stated in a statement on Tuesday that the molecule inhibits the synthesis of Lp(a). In China, HRS-5346 is presently undergoing evaluation in a Phase II study. Merck also did not disclose any precise intentions for the asset's development.